Skip to main content
. 2020 Aug 28;15(4):323–330. doi: 10.4103/1735-5362.293510

Fig. 1.

Fig. 1

Effect of pramlintide on HUVECs viability evaluated by MTT method. Cells were treated without or with pramlintide (1-20 μg/mL) for 24 h. Data are shown as means ± SEM from triplicate experiments. HUVECs, human umbilical vein endothelial cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.